key: cord-0808386-9x1h1ekk
authors: Hall, Ross; Guedán, Anabel; Yap, Melvyn W.; Young, George R.; Harvey, Ruth; Stoye, Jonathan P.; Bishop, Kate N.
title: SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export
date: 2022-02-09
journal: bioRxiv
DOI: 10.1101/2022.02.08.479664
sha: d68f88f5e6f1717305395a7724e69144f98a91c2
doc_id: 808386
cord_uid: 9x1h1ekk

SARS-CoV-2 is a betacoronavirus and the etiological agent of COVID-19, a devastating infectious disease. Due to its far-reaching effect on human health, there is an urgent and growing need to understand the viral molecular biology of SARS-CoV-2 and its interaction with the host cell. SARS-CoV-2 encodes 9 predicted accessory proteins, which are presumed to be dispensable for in vitro replication, most likely having a role in modulating the host cell environment to aid viral replication. Here we show that the ORF6 accessory protein interacts with cellular Rae1 to inhibit cellular protein production by blocking mRNA export. We utilised cell fractionation coupled with mRNAseq to explore which cellular mRNA species are affected by ORF6 expression and show that ORF6 can inhibit the export of many mRNA including those encoding antiviral factors such as IRF1 and RIG-I. We also show that export of these mRNA is blocked in the context of SARS-CoV-2 infection. Together, our studies identify a novel mechanism by which SARS-CoV-2 can manipulate the host cell environment to supress antiviral responses, providing further understanding to the replication strategies of a virus that has caused an unprecedented global health crisis. Author Summary SARS-CoV-2 is the virus responsible for the current COVID-19 pandemic. Coronaviruses, like SARS-CoV-2, replicate their genome in the cytoplasm of the host cell by hijacking the cellular machinery. In addition to structural proteins and viral enzymes, SARS-CoV-2 encodes 9 accessory proteins. Although these are not required for in vitro replication, they are thought to modulate the host cell environment to favour viral replication. In this work, we show that the ORF6 accessory protein can supress cellular protein production by blocking mRNA nuclear export through interacting with the cellular protein Rae1, a known mRNA export factor. We also investigated which cellular mRNAs were retained in the nucleus when ORF6 was overexpressed. Interestingly, we found that ORF6 inhibited the export of many different mRNAs, including those encoding antiviral factors, like IRF1 and RIG-I, even in the absence of stimulation by interferon. Importantly, we found that the export of these mRNAs was similarly affected in the context of SARS-CoV-2 infection. Therefore, we believe we have identified a novel mechanism that SARS-CoV-2 uses to suppress antiviral responses in order to make the cell more permissive to infection.

7 143 M58A, E59A and D61A also had a much weaker effect on mApple expression compared to 144 wild type ORF6 (Fig S1C) . (Fig 3C) . These genes were found to 225 include a wide range of Gene Ontology (GO) terms (Fig 3D) , highlighting their breadth of 226 function. These data suggest that ORF6 not only inhibits mRNA export of exogenous mRNA 227 such as GFP but, more importantly, also inhibits the nuclear export of a broad range of cellular 228 mRNA. 303 This could make them good therapeutic targets. These proteins are not well characterised for 304 SARS-CoV-2, so we decided to investigate their function. To do this, we generated a panel of 305 lentiviral VLPs encoding each individual accessory protein with which to introduce each 306 protein into various cells for defined functional assays. Interestingly however, we were 307 repeatedly unable to generate VLPs encoding ORF6 (Fig 1A) . We therefore determined how 308 ORF6 inhibits VLP production. We showed that ORF6 not only supresses expression of the 309 HIV-1 structural protein Gag, which is required for VLP synthesis, but it also reduced MLV 310 Gag (S1 Fig) and mApple expression (Fig 1D) , implying that ORF6 blocks protein expression 311 more broadly, in a sequence-independent manner.

Protein expression could have been inhibited via multiple mechanisms, however, ORF6 313 has been reported to interact with Rae1 and Nup98 which are involved in nuclear import and 314 export suggesting that ORF6 may modulate mRNA nuclear export resulting in decreased 315 protein expression. We confirmed that ORF6 from both SARS-CoV-2 and SARS-CoV-1 316 interacted with Rae1, and that this interaction was important for the block to protein expression 317 as mutants that were unable to interact also failed to inhibit protein expression (Figs 2 and 1F ).

318 Furthermore, we showed directly that ORF6 did indeed inhibit mRNA export (Figs 3 and 4) . 

Blocking cellular mRNA nuclear export, thereby reducing translation of cellular 327 proteins, would be advantageous for viral replication as SARS-CoV-2 replicates in the 328 cytoplasm and would therefore be able to exploit the limited cellular translational machinery 329 in favour of viral translation (Fig 6A) . In addition, by blocking mRNA export, ORF6 can also 330 affect other cellular processes beyond export, as inhibiting the translation of key cellular 331 proteins will modulate their downstream processes. Excitingly, using RNAseq, we have 332 revealed that ORF6 can prevent the nuclear export of mRNAs encoding antiviral factors (Fig   333 4) , both after IFN treatment, for example IFITM2 and ZNFX1, and more provocatively, in 334 untreated cells. This implies that ORF6 can modulate the basal, steady state level of immunity 335 in cells. Indeed, DDX58(RIG-I) and ZNFX1, which were enriched in the nucleus following 336 both ORF6 expression in untreated cells (Fig 4) and during SARS-CoV-2 infection (Fig 5) , are 337 key pattern recognition receptors (PRRs) that detect viral dsRNA [23, 24]. ZNFX1 has been 338 postulated to be involved in the very early stages of IFN signalling, as one of the earliest viral 339 sensors, due to its higher constitutive expression compared to both MDA5 and RIG-I [23].

340 Downregulation of these sensors would prevent the induction of an antiviral state and allow 341 SARS-CoV-2 to replicate undetected (Fig 6B) . The constitutively expressed transcription 342 factor, IRF1, which helps regulate basal expression of antiviral factors like BST2 and RIG-I 

HA-Rae1 was detectable in the eluate when co-expressed with ORF6, confirming an 169 interaction between these two proteins. Rae1 was detectable whether Nup98 was co-expressed 170 or not, suggesting that the ORF6 interaction with Rae1 is not dependent on Nup98. Conversely, 171 Nup98 was only detectable in the eluate when co-expressed with both ORF6 and Rae1

This suggests that the interaction between Nup98 and ORF6 is not direct but is instead 174 dependent on Rae1. Importantly, the Rae1(R305G) mutation that conferred resistance to 175 ORF6-dependent inhibition of protein expression (Fig 2A) did not co-immunoprecipitate with

ORF6 (Fig 2C) and Nup98 was also not present under these conditions, confirming that Nup98 177 interacts with ORF6 via Rae1

As expected, ORF6 and ORF6(E55A), which both inhibited Gag expression 179 (Fig 1F), co-immunoprecipitated with Rae1 whilst ORF6(M58A) did not

Additionally, we also observed that ORF6(CoV-1) co-immunoprecipitated with Rae1

and that both ORF6 homologues co-immunoprecipitated with endogenous Rae1

Overall, this implies that the effect of ORF6 on protein expression is mediated through 183 an interaction with Rae1, suggesting that the block is to mRNA export

To investigate the effect of ORF6 on mRNA export directly, we first set up an assay to separate 187 nuclear (Nucl) and cytoplasmic (Cyto) fractions and measure mRNA levels in each by qPCR

Cyto mRNA compared to the control would suggest that the mRNA is 189 being retained in the nucleus. As a proof-of-principle, we treated cells with Leptomycin B 190 (LMB), which inhibits Chromosomal Maintenance 1 (CRM1)-dependent mRNA export

HEK293T cells were transfected with a plasmid expressing GFP, treated with LMB 192 for 16 hrs and then fractionated. LMB clearly reduced GFP expression in cells

Although total GFP RNA levels were reduced, LMB-treated cells also had a higher 195 Nucl:Cyto GFP mRNA ratio compared to untreated cells

Like LMB-treated cells, cells expressing ORF6 also reduced GFP expression (S3E and F Fig) 197 and increased the ratio of Nucl:Cyto GFP mRNA (S3G and H Fig), while cells expressing 198 ORF6(M58A) had a similar Nucl:Cyto GFP mRNA as the control cells expressing ORF9b

Overall, this indicates that ORF6 inhibits nuclear export of GFP mRNA, in a Rae1-dependent 200 manner

To investigate whether ORF6 203 also inhibits endogenous cellular mRNA export, and to determine whether specific proteins are 204 affected, we performed mRNAseq on nuclear and cytoplasmic fractions of HEK293T cells 205 either untransfected (mock) or transfected with ORF6 or GFP. Transfections were performed 206 in duplicate and after 24 hrs, one sample for each transfection was treated with IFN-β (1,000 207 units/ml) for 16 hrs

Lysates were analysed by immunoblotting with anti-Strep antibodies to 210 confirm ORF6/GFP expression, HSP90 (cytoplasmic marker) and lamin B1 (nuclear marker), 211 to confirm that cellular fractionation was successful and phosphorylated STAT1 (pSTAT-212 Y701) to confirm activation of the type-I IFN signalling cascade

This was probably 281 linked to the poor viability of SARS-CoV-2(delta)-infected cells. In order to investigate mRNA 282 export, we chose eight genes to analyse from our mRNAseq data: We identified three mRNAs 283 that were most enriched in the nucleus in the presence of ORF6 (FAM222A, SPOCK1, 284 SERTAD1, together classed "non-antiviral") (S6E Fig, red dots) as well as four mRNA 285 encoding antiviral IUGs that were significantly enriched in the nucleus (RIG-I, IRF1, ZNFX1 286 and TRIM38) (Fig 4B, red dots). GAPDH was not significantly enriched in the nucleus with 287 ORF6 and so was used as a control. Overall, all four SARS-CoV-2 variants increased the 288 average Nucl:Cyto ratio of FAM222A, SPOCK1 and SERTAD1 mRNAs compared to 289 uninfected cells (Fig 5B) while the Nucl:Cyto ratio of GAPDH mRNA remained constant

Mus dunni tail fibroblast (MDTF) and Vero cell lines were maintained in

Dulbecco's modified Eagle medium (DMEM, Thermo Fisher), supplemented with 10% heat-372 inactivated foetal bovine serum (FBS, Biosera) and 1% Penicillin/Streptomycin (Sigma)

SARS-CoV-2 ORF accessory proteins were expressed in cells via transfection or transduction 378 with retroviral VLPs. The plasmids used to generate HIV-1 and MLV VLPs for transduction 379 of ORFs

For expression of each SARS-CoV-2 ORF accessory protein, two different plasmids were 381 used. For the initial experiments on Gag expression (Figs 1A-C and S1A and B Figs) and ORF6 382 co-expression with Rae1 (Fig 2A), a pLVX-IRES-Puro vector encoding an individual ORF 383 was used. The ORF genes were initially synthesised by GeneArt (Thermo Fisher) and first 384 cloned into a pTriEX-6 plasmids using XmaI and SacI restriction sites

ORF-IRES-Puro plasmids were then cloned using the NEBuilder HiFi DNA Assembly Cloning

Kit (NEB) from the pTriEX-6 plasmids, using the primers listed in Table 1. For the remaining 387 assays that required ORF detection or immunoprecipitation

ORF-2xStrep/2xStrep-ORF -IRES-Puro encoding one of the nine ORFs or pLVX-EF1α-eGFP-389 2xStrep-IRES-Puro plasmid was used, referred to as twin-strep-tag

To generate the pLVX-EF1α-CoV-1-ORF6-2xStrep-IRES-Puro plasmid

Virus-like particles (VLP) production

HIV-1 and MLV virus-like particles were generated by co-transfecting HEK293T cells with 409 plasmids, pCMVΔ8.91 (HIV-1) or pHIT60 (MLV) and pVSV-G using lipofectamine 2000 410 (11668019, Invitrogen). For generating GFP reporter VLPs

The plasmids were used at a ratio of 1:1:1

After 16 hrs, cells were treated with 10 mM sodium butyrate for 8 hrs, and supernatant 413 containing VLPs harvested 24 hrs later. To measure viral titres, HeLa cells were transduced 414 with serially diluted supernatant containing the VLPs. After 72 hrs, cells were selected with 415 media containing puromycin (1 μg/ml) for 10 days

Cells were lysed in ice cold radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher) or 421 IP buffer (50 mM Tris-HCl, pH 7.4 at 4 °C, 150 mM NaCl, 1 mM EDTA supplemented with 422 0.5% Nonidet P40) containing protease inhibitor cocktail (Roche) and DNAse

Protein lysates were boiled at 95 °C for 5 mins in 6x SDS sample buffer 424 (Thermo Scientific)

) and transferred to a PVDF membrane

Primary antibodies used were: anti-HIV-1 p24 (ARP432, CFAR)

C29F4, CST), anti-Strep-tag (34850, Qiagen), anti-HSP90 (4874, CST)

anti-Nup98 (C39A3, CST), anti-Rae1 (ab124783, Abcam), anti-pSTAT(Y701) 430 (D4A7, CST)

anti-sheep (ab6747, Abcam) and anti-rabbit

Thermo Fisher) HRP-conjugated; anti-mouse IRDye 680RD/800CW

-Cor) and anti-rabbit IRDye 700CW/800CW

HEK293T cells were grown in 10 cm 2 culture plates transfected and incubated for 16 hrs after 439 which media was replaced. After a further 8 hrs, cells were harvested in Pierce IP lysis buffer 440

Twin-strep fusion proteins were immunoprecipitated with MagStrep "type3" XT beads 442 (IBA) as per the manufacturer's instructions. Proteins were eluted with biotin (50 mM) and transfected with psfGFP-N1 and either treated with LMB (Merck) at 447 5nM

Each 451 sample was then split in two: half was used for protein analysis and half was used for RNA 452 extraction. Protein content in the total cell lysate and in the fractions was measured by BCA 453 assay (Thermo Fisher) using a FLUOstar Omega plate reader (BMG Labtech)

Quantitative PCR 461 (qPCR) analysis was performed in TaqMan Fast Advanced master mix (Thermo Fisher) with 462 900nM primers and 250nM probes, or 1X Taqman gene expression assays. The reactions were 463 performed on a 7500 fast real-time PCR system (Applied Biosystems) using standard cycling 464 conditions: 50 °C for 2min, 95 °C for 10min followed by 40 cycles of 95 °C for 15s and 60 °C 465 for 1min. To calculate DNA copy numbers, standard curves were generated from serial 466 dilutions of the indicated cDNA in water. The following primers and probes were used

Only samples with 473 a RINe of 7 or higher were used for Library preparation. RNA-seq libraries were generated 474 using the NEBNext Ultra Directional RNA Library Prep kit for Illumina with NEBNext®

Samples were 476 adjusted to 400 ng total RNA and spiked with diluted 1/100 ERCC Spike-In Mix

Invitrogen) and Drosophila melanogaster, embryo Poly A+ RNA, 5 μG (636224-Takara) using

PCR Enrichment of Adaptor Ligated DNA was run with 12 cycles and SPRI 479 beads (Beckman) were used for library clean up

Technologies) were used to check library size and quality. Samples were sequenced on an 21

Illumina Novaseq 6000 platform with 180 pM loading concentration in single-end run using 482 100-bp reads. Enriched GO terms (Biological process) were filtered and mapped using the

The raw RNAseq data from this study can

Ensembl 488 BDGP6.104) genomes was prepared, and reads were trimmed, aligned, and counts produced 489 using the nf-core rnaseq pipeline [42]. Normalisation and differential expression analyses were 490 conducted within DESeq2 [43]: normalisation factors for gene-level read counts were produced 491 using counts for the D. melanogaster spike-in controls and differential gene expression 492 calculations were subsequently performed for Human genes alone using the pre-calculated size 493 factors

/2) was the hCoV-19/England/02/2020, obtained from the Respiratory Virus Unit, 500 Public Health England, UK (GISAID EpiCov accession EPI_ISL_407073). The B.1.1.7 501 (Alpha) isolate was the hCoV-19

K417N, E484K, N501Y, A701V mutations, and was 22 506 kindly provided by Prof. Alex Sigal and Prof. Tulio de Oliveira [47], sequencing of viral 507 isolates received identified the Q677H and R682W mutations at the furin cleavage site in 508 approximately 50% of the genomes

B.1.617.2 (Delta) isolate was MS066352H (GISAID accession number EPI_ISL_1731019), 510 which carries the T19R, K77R, G142D, Δ156-157/R158G, A222V, L452R, T478K, D614G, 511 P681R, D950N, and was kindly provided by Prof

UK through the Genotype-to-Phenotype National Virology Consortium (G2P-UK)

Viruses were titrated by plaque assay on Vero E6 cells. Serial ten-fold dilutions of virus are 514 incubated for 40 mins at RT on a well of confluent Vero E6 cells. The virus inoculum is then 515 removed, and the cells overlayed with a semisolid overlay containing 1

Cells are incubated for two days at 37 °C, 5 % CO 2 after which the overlay is removed. Cells 517 were fixed and stained with 4 % paraformaldehyde containing 0.2 % toluidine blue for at least 518 30 mins. For the infections, Vero E6 cells were seeded 24 hrs before use

Cells were washed, medium was removed from each well and 1 ml of serum-free 520 DMEM added. The 1 ml of serum-free DMEM was removed and 500 µl virus diluted in virus 521 growth medium was added to achieve an MOI of ≥1. Plates were incubated for approx. 30 mins 522 at RT and then 1 ml virus growth medium was added to each well. Plates were incubated for 523 24 hrs before RNA isolation and qPCR as described above using Taqman gene expression 524 assays

SERTAD1 (Hs00203547_m1), ZNFX1 (Hs01105231_m1)

GAPDH (Hs02786624_g1) and IRF1 coverslips and transfected or infected with SARS-CoV-531 2. Cells were fixed in 4% PFA in PBS for 10 mins at RT. Cells were then permeabilised with 532 0.1% triton in PBS and blocked in 3% BSA in PBS. Cells were labelled with the following 533 primary antibodies, anti-Nup98 or anti-ORF6

Cells were then incubated with the following secondary antibodies, donkey anti-rabbit-AF568 535 (ab175692, Abcam) and donkey anti-sheep AF568 (A-21099, Invitrogen) diluted in 4% BSA 536 in PBS for 1 hour at RT. Coverslips were washed and mounted on glass coverslips with

ProLong Gold Antifade Mountant with DAPI (Thermo Fisher) and imaged with the Leica SP5

Statistical analysis was performed using GraphPad Prism 9 software

#141392-95) and Wendy Barclay, Prof. Alex Sigal 547 and Prof. Tulio de Oliveira for providing SARS-CoV-2 viral isolates. We are extremely 548 grateful to Jimena Perez-Lloret, Robert Goldstone and Deb Jackson from the Crick ASF STP 549 for running the RNAseq experiment

This work was supported by the Francis Crick Institute, which receives its core funding from 555 Cancer Research UK (FC001042, to KB and FC001162, to JS), the UK Medical Research

and the Wellcome trust (FC001042, to KB 557 and FC001162, to JS) and by the MRC Genotype-to-Phenotype (G2P) UK National Virology 558 Consortium grant to KB (MR/W005611/1) and by a Wellcome Trust Investigator Award to JS 559 (108012/Z/15/Z). The funders had no role in study design, data collection and analysis

Genomic characterisation and 565 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor 566 binding. The Lancet

Pathological findings 569 of COVID-19 associated with acute respiratory distress syndrome. The Lancet 570 Respiratory Medicine

A pneumonia 575 outbreak associated with a new coronavirus of probable bat origin

A 578 SARS-CoV-2 protein interaction map reveals targets for drug repurposing

SARS Coronavirus Accessory Gene Expression 581 and Function

Accessory proteins of

Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF)

ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists

Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1

Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic

Orf6 hijacks Nup98 to block STAT nuclear import and antagonize 597 interferon signaling

The of Poly(A)+ RNA

RAE1 Is a 604 Shuttling mRNA Export Factor That Binds to a GLEBS-like NUP98 Motif at the 605 Nuclear Pore Complex through Multiple Domains

Her L. Inhibition of Ran Guanosine Triphosphatase-Dependent Nuclear 611 Transport by the Matrix Protein of Vesicular Stomatitis Virus

Vesicular Stomatitis Virus Matrix Protein Inhibits Host Cell Gene Expression by 615 Targeting the Nucleoporin Nup98

Influenza virus targets the mRNA export machinery and the nuclear pore 619 complex

SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression

SARS-CoV-2 ORF6 Disrupts Bidirectional Nucleocytoplasmic Transport through

Interactions with Rae1 and Nup98. mBio

Overexpression of SARS-CoV-2 protein ORF6 dislocates RAE1 and NUP98 from the 630 nuclear pore complex

Structural and functional analysis of the 633 interaction between the nucleoporin Nup98 and the mRNA export factor Rae1

CRM1, a nuclear export receptor, in mRNA export in mammalian cells and fission 638 yeast

Selectively Inhibits Cellular mRNA Nuclear Export

The RNA helicase RIG-I has an essential function in double-stranded RNA-647 induced innate antiviral responses

Central role of interferon 650 regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) 28

Maintains Optimal Constitutive Expression of Antiviral Genes and Regulates the

Activation 658 of IFN-βelement by IRF-1 requires a post-translational event in addition to IRF-1 659 synthesis

Degradation of transcription factor IRF-1 by the 662 ubiquitin-proteasome pathway

Pine R. Constitutive expression of an ISGF2/IRF1 transgene leads to 669 interferon-independent activation of interferon-inducible genes and resistance to 670 virus infection

Severe Acute Respiratory Syndrome

Coronavirus Accessory Protein 6 Is a Virion-Associated Protein and Is Released 674 from 6 Protein-Expressing Cells

The ORF6, ORF8 and 680 nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

Activation and evasion of 683 type I interferon responses by SARS-CoV-2

Purification and 686 cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 transcriptional activator of either

CoV-2 uses a multipronged strategy to impede host protein synthesis

The interplay of nuclear mRNP assembly, mRNA surveillance and 695 export

A transient three-plasmid expression system for the production of high titer 699 retroviral vectors

In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector

703 efficient long-term transduction of corneal endothelium and retinal pigment 704 epithelium

Visualizes Long Lists of Gene Ontology Terms

The nf-712 core framework for community-curated bioinformatics pipelines

Moderated estimation of fold change and 715 dispersion for RNA-seq data with DESeq2

Data-driven hypothesis weighting 718 increases detection power in genome-scale multiple testing

False discovery rates: a new deal

Increased transmission of SARS-CoV-2 lineage B

Escape of 727 SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

A) To generate VLPs, HEK293T cells were co-transfected with plasmids encoding HIV-1

VSV-G and a pLVX-StrepII-ORF vector encoding either SARS-CoV-2 ORF3a

ORF9c or ORF10 or an empty vector control

VLPs were harvested and titrated in HeLa cells. The infectious units/ml are shown in the bar 738 graph. Points indicated independent biological repeats. Transfected cell lysates were separated 739 by SDS-PAGE and analysed for Gag(HIV-1) and HSP90 by immunoblotting

VSV-G and either increasing 741 amounts of pLVX-StrepII-ORF6 or pLVX-StrepII-ORF9b as well as a GFP reporter plasmid, 742 pCSGW. (B) Transfected cell lysates were separated by SDS-PAGE and analysed for

Three days post infection, the percentage of GFP strep-tagged GFP(Control), ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, 748 ORF9c or ORF10 and a plasmid encoding mApple. After 48h, cells were fixed and the mApple 749 median fluorescent intensity (MFI) measured by flow cytometry. The fold change (FC) in MFI 750 is plotted relative to the control for independent biological repeats

Transfected cell lysates were analysed by SDS-PAGE and immunoblotting with anti-strep

Amino acid alignment of the C-terminus region of ORF6 from SARS-CoV-2 and SARS-CoV-1 753 with conserved residues highlighted in red. (F) HEK293T cells were transfected with pLVX-754 EF1α encoding strep-tagged ORF9b, ORF6(CoV-2), ORF6(CoV-1) or indicated ORF6(CoV-755 2) mutant and a plasmid encoding HIV-1 Gag-Pol. After 24h, cell lysates were separated by 756 SDS-PAGE and analysed for Gag

Fig 2. ORF6 inhibits protein expression by interfering with Rae1

After 48h, cell 761 lysates were separated by SDS-PAGE and analysed for Gag(HIV-1), Rae1, ORF6 or ORF9b 762 and HSP90 by immunoblotting. (B) HEK293T cells were transfected with plasmids encoding 763 Twin-Strep-tagged GFP or ORF6 and Nup98 and/or HA-Rae1. After 24h, Twin-Strep-tagged 764 proteins were immunoprecipitated with MagStrep beads and proteins eluted with biotin. Input 765 lysates and eluate were separated by SDS-PAGE and analysed by immunoblotting for Strep, 766 Nup98 and HA. (C) HEK293T cells were transfected with plasmids encoding Twin-Strep-767 tagged GFP or ORF6

Strep-tagged proteins were immunoprecipitated and analysed as in (C). (D) HEK293T cells 769 were transfected with plasmids encoding Twin-Strep-tagged proteins

After 24h, Twin-Strep-tagged 771 proteins were immunoprecipitated with MagStep beads and input lysates and eluates separated 772 by SDS-PAGE and analysed by immunoblotting for Strep and HA

775 HEK293T cells were transfected with pLVX-EF1α-GFP or pLVX-EF1α-ORF6 or left 776 untransfected (mock)

Cells were then harvested and fractionated into nuclear (Nucl) and 778 cytoplasmic (Cyto) fractions. Cells were either lysed for immunoblot analysis (see S4A Fig)

The 782 log2-FC in mRNA abundance was then directly compared between ORF6 and GFP, without 783 (left panel) and with (right panel) IFN, to determine which mRNAs were specifically enriched 784 in the nucleus or cytoplasm by ORF6. The log-2FC was weighted against the adjusted p-value 785 (shrunken Log2-FC) to show significantly enriched mRNAs (yellow points). The number of 786 mRNAs significantly enriched is shown. The mRNA count was normalised and averaged 787 between the three biological repeats. (C) Venn diagram of the number of mRNAs that were 788 significantly enriched in the nucleus by ORF6 with and without IFN. (D) mRNAs significantly 789 enriched by ORF6 without IFN treatment were analysed for enriched GO terms

These IUGs were 796 then compared to the list of mRNAs that were significantly upregulated or downregulated by 797 ORF6 compared to the GFP control (see S5E Fig), in either the Cyto (upper panel) or Nucl 798 (lower panel) fractions. The heat maps show the relative Log2-Fold Change in IUG expression 799 in cells expressing GFP (Control) or ORF6 after IFN treatment

Venn diagram showing the number of IUG mRNAs that were significantly enriched in the 801 nucleus by ORF6 with and without IFN treatment. (C) The log2-fold change (Log2-FC) in 802 mRNA abundance was calculated between the Nucl and Cyto fractions for both GFP and ORF6 803 expressing cells, without and with IFN treatment, as in Fig 3B, to determine which mRNA 804 were specifically enriched by ORF6. The log-2FC was

Vero cells were inoculated with four SARS-CoV-2 variants

A) Cells were fixed and analysed by immunofluorescence with anti-ORF6 811 and DAPI. (B) Cells were fractionated, RNA was extracted, and cDNA was generated. mRNA 812 levels of four non-antiviral (orange) and four antiviral (blue) proteins in both Nucl and Cyto 813 fractions were measured by qPCR. The ratio of Nucl to Cyto mRNA was calculated and plotted

Points indicate individual biological repeats and error bars show the mean ± SEM

This subsequently reduces 821 the cellular mRNA pool, increasing the availability of cellular translational machinery for viral 822 translation as well as decreasing the expression of cellular proteins

This prevents the translation of IRF1, blocking IRF1 35 825 regulation of the transcription of additional steady state antiviral factors, like RIG-I and BST-826 2. ORF6 also inhibits nuclear export of mRNA encoding RIG-I (green), preventing detection 827 of viral dsRNA produced during coronavirus replication. This helps reduce IRF1/3/7 activity 828 and subsequent transcription of IFNα/β (purple)

SARS-CoV-2 ORF6 Inhibits MLV Gag expression

HEK293T cells were transfected with plasmids encoding 834 Gag-Pol(MLV), VSV-G and either increasing amounts of pLVX-StrepII-ORF6 or pLVX

VLPs 836 were generated with an empty pLVX vector. (A) Transfected cells were lysed and analysed 837 by SDS-PAGE and immunoblotting for Gag(MLV), ORF6 or ORF9b and HSP90. (B) MDTF 838 cells were infected with increasing amounts of MLV VLPs. Three days post infection, the 839 percentage of GFP positive cells was determined by flow cytometry. Graph shows the mean 840 and range of two biological repeats

CoV-2) or the indicated ORF6 mutant 842 as well as a plasmid encoding mApple. After 48h, cells were fixed and the mApple MFI 843 measured by flow cytometry. The fold change (FC) in MFI is plotted relative to the control 844 for independent biological repeats

CoV-2) or ORF6(CoV-1) and HA-Rae1. After 24h

Input lysates and 851 eluate were separated by SDS-PAGE and analysed by immunoblotting for Strep, Nup98 and 852 HA. (B) HEK293T cells were transfected with the pLVX-EF1α plasmid encoding Twin

Strep-tagged GFP or ORF6. After 24h, tagged proteins were immunoprecipitated with

Input lysates and eluate were separated by 855 SDS-PAGE and analysed by immunoblotting for endogenous Rae1 and anti-Strep

ORF6 inhibits GFP mRNA export in a Rae1-dependent manner

After 16h, cells 860 were either harvested as a total cell lysate (T) or fractionated into Nucl (N) and Cyto (C) 861 fractions. Total cell lysates and cellular fractions were divided into two for either protein 862 analysis (B) or RNA extraction (C,D). (A) Low magnification fluorescent images showing 863 GFP expression in transfected cells before harvest. (B) Protein levels were quantified by 864 BCA assay

RNA from Nucl and Cyto fractions was converted into cDNA and GFP mRNA copy 867 numbers measured by qPCR. (D) The ratio of Nucl to Cyto GFP mRNA was calculated and 868 plotted for individual biological repeats

After 32h, cells were either harvested as a total cell lysate 871 (T) or fractionated into Nucl (N) and Cyto (C) fractions. Total cell lysates and cellular 872 fractions were divided into two for either protein analysis (F) or RNA

Low magnification fluorescent images showing GFP expression in transfected cells before 874 harvest. (F) Protein levels were quantified by BCA assay, proportional amounts of the 37 875 fractions related to the total cell lysate were analysed by immunoblotting for Strep, GFP, 876 HSP90 (cytoplasmic marker) and Histone H3 (nuclear marker). (G) RNA from Nucl and 877 Cyto fractions was converted into cDNA and GFP mRNA copy numbers measured by qPCR

H) The ratio of Nucl to Cyto GFP mRNA was calculated and plotted for individual 879 biological repeats. Error bars show the mean ± SEM. Significance was calculated by one-way 880 ANOVA with Turkey's post hoc test

ORF6 inhibits the nuclear export of cellular mRNA

The cell fractionations used in Fig 3A, and B were analysed by immunoblotting with 884 anti-Strep to label ORF6 and GFP, anti-pSTAT(Y701) to confirm activation of the type-I IFN 885 signalling cascade and anti-HSP90 (cytoplasmic marker) or anti-Lamin B1 (nuclear marker) 886 to confirm successful fractionation

From the mRNAseq data in Fig 3. The log2-fold change (Log2-FC) in mRNA abundance was 888 compared between the Nucl and Cyto fractions for both GFP and ORF6 expressing cells, 889 without (upper panels) and with IFN treatment (lower panels). The log-2FC was weighted 890 against the adjusted p-value (shrunken Log2-FC) to show mRNAs

ORF6 inhibits the nuclear export of IFN-upregulated mRNA

From the mRNAseq data in Fig 3. The Log2-FC in mRNA abundance was compared 897 between cells treated with IFN or left untreated in both the Cyto (left panel) and Nucl (right 898 panel) fractions. The log-2FC was weighted against the adjusted p-value

Cyto. and Nucl. fractions. (C) GO ontology enrichment analysis of significantly upregulated

IUGs from A. in both the Cyto and Nucl fractions. (D) Venn diagram showing the number of

IUGs significantly downregulated (red) or upregulated (green) by ORF6 in Cyto. and Nucl

From the mRNAseq data in Fig 3. The log2-fold change 906 (Log2-FC) in mRNA abundance was compared between ORF6 and GFP expressing cells in 907 the Cyto. and Nucl fractions, without (upper panel) and with IFN treatment

This log2-FC was weighted against the adjusted p-value (shrunken Log2-FC) to identify 909 significantly upregulated/downregulated mRNAs (in yellow), with the number of mRNAs 910 shown. The mRNA count was normalised and averaged between the three biological repeats

SARS-CoV-2 inhibits the export of cellular mRNA 913 (A) Vero cells that were inoculated with SARS-CoV-2(beta) in Fig 5A were fixed, 914 permeabilised and analysed by immunofluorescence with anti-Nup98, anti-ORF6 and DAPI

Cell lysates from Fig 5B were analysed by immunoblotting for Strep to label ORF6

Nuclear marker) to confirm successful 917 fractionation. The analysis of three biological repeats are shown. (E) The plot shown in Fig 918 3B (right panel) highlighting the enrichment of the mRNA encoding the four non-antiviral 919 proteins that were quantified by qPCR in Fig 5B